{
    "nctId": "NCT00024154",
    "briefTitle": "Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "A Phase I/II Trial of Herceptin and ZD1839 (Iressa, NSC #715055, IND#61187) in Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu (erbB-2)",
    "overallStatus": "COMPLETED",
    "conditions": "Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 132,
    "primaryOutcomeMeasure": "MTD and DLT in patients treated with Herceptin and ZD1839 graded using the NCI CTC (Phase I)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed metastatic adenocarcinoma of the breast\n\n  * Patients may have had or not had standard first-line chemotherapy for the treatment of metastatic disease\n* Overexpression of HER2-neu (HER2 3+ by immunohistochemistry or gene amplification as measured by fluorescent in situ hybridization)\n* Measurable disease\n* Patients with no prior adjuvant chemotherapy may have failed or not failed first-line chemotherapy for metastatic disease\n* No more than 2 prior systemic chemotherapy regimens for metastatic disease\n\n  * Relapse while receiving or within 6 months of completion of adjuvant chemotherapy is considered failure of 1 regimen for metastatic disease\n* No untreated brain metastases or brain metastases undergoing radiotherapy\n\n  * Previously treated brain metastasis that has responded to radiotherapy and/or surgery allowed if not sole site of measurable disease\n* Hormone receptor status:\n\n  * Not specified\n* Male or female\n* Performance status - ECOG 0-2\n* Granulocyte count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* AST and ALT no greater than 3 times ULN (5 times ULN if liver metastases is present)\n* INR no greater than 1.5 times ULN\n* PT and PTT no greater than 1.5 times ULN\n* Creatinine no greater than 1.5 mg/dL\n* No more than trace blood or protein in urine\n* LVEF \u2265 50% by MUGA scan\n* No prior New York Heart Association class I-IV heart disease\n* No PR prolongation or atrioventricular block on ECG\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception (preferably nonhormonal)\n* Random blood sugar less than 2.5 times ULN\n* No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No other acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation\n* No prior trastuzumab (Herceptin)\n* No other concurrent immunologic therapy\n* See Disease Characteristics\n* Recovered from prior cytotoxic chemotherapy\n* No prior cumulative dose of doxorubicin more than 360 mg/m\\^2\n* No concurrent chemotherapy\n* At least 2 weeks since prior hormonal therapy\n* No concurrent hormonal therapy, including tamoxifen\n* No concurrent dexamethasone, progesterone, or glucocorticoids\n* See Disease Characteristics\n* At least 2 weeks since prior radiotherapy\n* No prior radiotherapy to target lesions or only site of measurable disease\n* No concurrent radiotherapy\n* See Disease Characteristics\n* No prior organ allograft\n* No prior gefitinib\n* No prior immunosuppressive therapy\n* At least 2 weeks since prior cytotoxic drugs\n* No concurrent carbamazepine, ethosuximide, griseofulvin, nafcillin, nelfinavir mesylate, nevirapine, oxcarbazepine, phenobarbital, phenylbutazone, phenytoin, primidone, rifabutin, rifampin, rofecoxib, Hypericum perforatum (St. John's Wort), sulfadimidine, sulfinpyrazone, troglitazone, or grapefruit juice\n* No other concurrent investigational agents\n* No concurrent topical eye agents\n* Concurrent bisphosphonates allowed for hypercalcemia and/or prophylaxis of bone metastases",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}